Your browser doesn't support javascript.
loading
Deletion of Endogenous Neuregulin-4 Limits Adaptive Immunity During Interleukin-10 Receptor-Neutralizing Colitis.
Bernard, Jessica K; Bucar, Edie B; Liu, Cambrian Y; Katada, Kay; Washington, Mary K; Schumacher, Michael A; Frey, Mark R.
Afiliação
  • Bernard JK; Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA.
  • Bucar EB; Craniofacial Biology Program, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
  • Liu CY; Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA.
  • Katada K; Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA.
  • Washington MK; Department of Medicine, University of Chicago, Chicago, IL, USA.
  • Schumacher MA; Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA.
  • Frey MR; Department of Pathology, Microbiology, and Immunology, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Inflamm Bowel Dis ; 29(11): 1778-1792, 2023 11 02.
Article em En | MEDLINE | ID: mdl-37265326
Neuregulin-4 (NRG4) is a growth factor that protects the epithelial cells lining the colon from injury and restrains innate (non-specific) immune responses. Here we show that NRG4's role in inflammation is context-specific, and mice that lack NRG4 have impaired adaptive immunity in a model of chronic immune-mediated colitis.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colite / Mucosa Intestinal Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colite / Mucosa Intestinal Idioma: En Ano de publicação: 2023 Tipo de documento: Article